A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results Abstract #1179

Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Aim(s): To evaluate the safety and efficacy of axitinib in patients with advanced carcinoid tumors
Materials and methods: We performed a phase II trial of axitinib 5 mg BID in patients with advanced low to intermediate grade carcinoid tumors. Prior antiangiogenic therapy with a dedicated VEGF pathway inhibitor was not permitted. The primary endpoints were PFS and 1-year PFS rate
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Mauro Cives

To read results and conclusion, please login ...

Further abstracts you may be interested in

#299 Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH)
Introduction: MTC and CCH has a variable clinical presentation and prognosis and no data are available on the correlation between immunoistochemical (IIC) characterization and clinical behavior.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Prof Laura De Marinis
Authors: Lugli F, Fusco A, Bianchi A, Milardi D, ...
#2011 Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: The expression of vascular endothelial growth factor Receptor 3 (VEGFR3) and phospho-VEGFR3 (pVEGFR3) in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and their clinical significance are still unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Y, Chen M, ...
#211 Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors
Introduction: Hepatic transarterial embolization is often recommended for patients with liver-predominant metastatic NETs. Antiangiogenic therapy following embolization may delay tumor revascularization.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#214 Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas
Introduction: The AJCC Cancer Staging Manual (7th edition, 2010) has introduced a novel TNM staging classification for pancreatic NETs. This classification has not yet been validated.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Cheema A, Weber J, Kvols L, ...
#217 Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors
Introduction: The risk of metastatic spread among patients with early-stage surgically resected pancreatic neuroendocrine tumors has not been well-established.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Cheema A, Weber J, Kvols L, ...